NY-ESTÉE-LAUDER
18.6.2020 15:32:11 CEST | Business Wire | Press release
Today, The Estée Lauder Companies (NYSE:EL) announced that Jane Lauder will be named to the new role of Executive Vice President, Enterprise Marketing and Chief Data Officer, effective July 1, 2020. She will report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC). Jane will be succeeded at Clinique by Michelle Freyre, who will join the brand as Senior Vice President, General Manager, effective July 1, 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005543/en/
As ELC’s first ever Enterprise Marketing and Chief Data Officer, Jane will lead our company-wide strategy to build our data-empowered, digitally-directed priorities to accelerate ELC’s growth. By optimizing our vast and valuable data and integrating the company’s analytic capabilities the goal is to drive breakthrough marketing and creative.
“We are focused on delivering the very best, high-quality products that leverage consumer insights from our enhanced data analytics, and I am confident that Jane is the right person to lead this important area of the business,” said Mr. Freda. “As Global Brand President of Clinique and leader of ELC’s enterprise-wide efforts to combine data-driven insights with creativity, she has successfully leveraged data and analytics capabilities to drive strong long-term growth at both the brand and enterprise level. Jane’s unique combination of understanding high-touch consumer experiences, and data analytics and insights, will further strengthen our innovative product offerings and experiences for our consumers globally. I look forward to working even more closely with Jane as she takes on this new role.”
Jane has over two decades of beauty industry experience, including more than 23 years at The Estée Lauder Companies. As Global Brand President of Clinique, she led the transformation of brand strategy, distribution, product innovation and consumer reach, positioning the brand for strong long-term growth. Under Jane’s leadership, Clinique fundamentally shifted nearly one-third of product revenue from low-growth distribution channels to high-growth channels and tripled Clinique’s online business. She also oversaw the development of product innovations including Moisture Surge™ 72-Hour Auto-Replenishing Hydrator and Clinique iD™ and technology innovations with Clinique Clinical Reality™ to strengthen the brand’s skincare position in clinical efficacy and high-touch services and personalization. Clinique’s market share gains in recent months across its core markets are a testament to the rebuilding of the brand.
Jane also leads ELC’s enterprise-wide transformation program focused on combining data and analytics capabilities with creativity to power ELC’s business and digital agenda. In her new role she will continue to drive this competency across the company. As a graduate of Stanford University and member of the Board of Directors of Eventbrite, a California-based global ticketing and event technology platform, Jane’s deep ties to Silicon Valley will be leveraged in her new role.
Jane’s organization will include BI&A, Corporate Marketing and Marketing and Consumer Supported Technology, a forward-looking portfolio management approach to data, marketing and consumer-facing technologies. ELC’s Business Insight & Analytics (BI&A) group will play a central role, and will report directly to Jane with a matrix line into Tracey T. Travis, Executive Vice President and Chief Financial Officer. Jane’s leadership will enable BI&A to continue to accelerate the Company’s ability to unlock value across brands, functions, partners and employees.
Jane will lead the global Corporate Marketing function, including the regional Corporate Marketing organizations, Consumer and Product Marketing Insights, Global Consumer Care and Marketing Planning and A&P effectiveness. She will enable the facilitation and free flow of data among business units to help these teams to mine, analyze and share strategic insights more effectively. She will also enhance the integration of cross-channel data to drive personalized marketing and true omni-channel activation.
Additionally, Jane and her team will ensure that ELC has access to cutting-edge digital innovations through a more formalized approach to strategic digital partnership management, including breakthrough marketing partnerships with leading organizations such as Facebook and Google. Her team will be scouting and developing relationships with emerging influential platforms and players in the marketing, digital innovation and consumer engagement space.
Finally, Jane will be charged with strategically deepening the company’s investments in Talent Management and Capabilities within the Marketing and Consumer Engagement teams, helping to drive talent development, recruitment and breakthrough learning and education programs, making ELC into a career destination of choice for best-in-class brand building, marketing and consumer engagement talent around the world.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20200618005543/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom